Natalie Houwing, MSc

Natalie holds a M.Sc. degree in Biopharmaceutical Sciences from the University of Leiden where she graduated in 1993 (specialization in pharmacology). After her graduation she worked in Research & Development of Organon, the pharmaceutical division of Akzo Nobel (now part of Schering-Plough corporation), for 12 years. During this period Natalie participated in multidisciplinary R&D teams as an expert on Clinical Pharmacology/Pharmacokinetics-Pharmacodynamics. In this function she was involved in the design of clinical development programs across a wide range of therapeutic areas including anesthesia (neuromuscular blocking agents, intravenous anesthetics, analgesics), central nervous system (depression, schizophrenia), and endocrinology (female and male hormone replacement therapy, osteoporosis, contraceptives). She represented her discipline at meetings with regulatory authorities (FDA, EMEA). She has extensive experience in designing, analyzing and reporting of clinical trials (clinical pharmacology studies, proof-of-concept studies, dose-finding and pivotal efficacy/safety trials) and in using their results to guide clinical development decisions, and to support registration and marketing. Within Organon, Natalie set up and headed a group specialized in advanced Pharmacokinetic-Pharmacodynamic modeling and clinical trial simulation for several years.

Natalie joined Pharmerit in 2007 and is a senior research consultant for several projects which draw on her comprehensive experience in Drug Development, with a focus on integrating Pharmacokinetic-Pharmacodynamic mechanisms into Cost-Effectiveness models.